Close Menu

Precision Oncology News

Kura Oncology said that it intends to enroll more patients for a registration-directed Phase II trial in 2020 following positive FDA feedback.

Olaparib is the first PARP inhibitor approved in China for first-line maintenance treatment of germline and somatic BRCA mutated gynecological cancers.

The approval is based on a Phase III trial showing that Tecentriq significantly improved survival in patients with metastatic non-small cell lung cancer.